- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisA Novotna
Krajská nemocnice Pardubice, Neurologicke odd, Paradubice, Czech Republic
Eur J Neurol 18:1122-31. 2011..Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design...